<p>在过去一个季度中，10 位分析师对 Viridian Therapeutics VRDN 表达了各种意见，提供了从看涨到看跌的多样化观点。</p>
<p>下表总结了他们最近的评级，揭示了过去 30 天内情绪的变化，并与前几个月进行了比较。</p>
<table>
<thead>
<tr>
<th></th>
<th><strong>看涨</strong></th>
<th><strong>稍微看涨</strong></th>
<th><strong>无所谓</strong></th>
<th><strong>稍微看跌</strong></th>
<th><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td>7</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
<p>分析师评估的 12 个月价格目标揭示了进一步的见解，平均目标为 41.2 美元，最高估计为 61.00 美元，最低估计为 34.00 美元。当前平均价格目标较之前的 39.70 美元上升了 3.78%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2024/1734458424_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2024/1734458424_0.png"/></p>
<h2>分析师评级调查：详尽研究</h2>
<p>通过最近的分析师行动分析金融专家对 Viridian Therapeutics 的看法。以下总结展示了关键分析师、他们的最新评估以及对评级和价格目标的调整。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>上调</td>
<td>超越市场</td>
<td>$47.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright \u0026 Co.</td>
<td>维持</td>
<td>买入</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright \u0026 Co.</td>
<td>维持</td>
<td>买入</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>维持</td>
<td>超越市场</td>
<td>$44.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>维持</td>
<td>买入</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright \u0026 Co.</td>
<td>上调</td>
<td>买入</td>
<td>$34.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>维持</td>
<td>买入</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>维持</td>
<td>买入</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Julian Harrison</td>
<td>BTIG</td>
<td>上调</td>
<td>买入</td>
<td>$61.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>维持</td>
<td>超越市场</td>
<td>$44.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>关键见解：</h3>
<ul>
<li><strong>采取的行动：</strong> 针对动态市场条件和公司表现，分析师更新他们的建议。无论是 “维持”、“上调” 还是 “下调”，都表明他们对 Viridian Therapeutics 近期发展的反应。这一见解提供了分析师对公司当前状态的快照。</li>
<li><strong>评级：</strong> 分析趋势，分析师提供定性评估，从 “超越市场” 到 “表现不佳”。这些评级传达了对 Viridian Therapeutics 相对于更广泛市场的表现预期。</li>
<li><strong>价格目标：</strong> 分析师提供对 Viridian Therapeutics 股票未来价值的估计。这一比较揭示了分析师预期随时间变化的趋势。</li>
</ul>
<p>将这些分析师评估与其他财务指标结合考虑，可以提供对 Viridian Therapeutics 市场地位的全面理解。保持信息灵通，做出明智的决策，参考我们的评级表。</p>
<p><strong>保持关注 Viridian Therapeutics 的分析师评级。</strong></p>
<p>如果您对跟踪小型股新闻和表现感兴趣，可以从这里开始。</p>
<h2>深入了解 Viridian Therapeutics：更近一步</h2>
<p>Viridian Therapeutics Inc 是一家临床阶段的生物制药公司，致力于开发多种产品候选药物，以治疗患有甲状腺眼病的患者。其产品候选药物 VRDN-001 是一种胰岛素样生长因子-1 受体（IGF-1R）单克隆抗体（mAb），正在开发中以潜在治疗甲状腺眼病患者。</p>
<h3>分析 Viridian Therapeutics 的财务表现</h3>
<p><strong>市值分析：</strong> 该公司的市值高于行业平均水平，反映出其规模庞大和市场认可度强。</p>
<p><strong>收入增长：</strong> Viridian Therapeutics 在过去 3 个月的收入增长显著。截至 2024 年 9 月 30 日，该公司的收入增长率约为 <strong>19.44%</strong>。这表明公司顶线收益的显著增加。与竞争对手相比，该公司的增长率低于医疗保健行业的平均水平，面临一定困难。</p>
<p><strong>净利润率：</strong> Viridian Therapeutics 的净利润率低于行业平均水平，表明在维持强劲盈利能力方面可能面临挑战。净利润率为 <strong>-89173.26%</strong>，公司在有效成本管理方面可能面临困难。</p>
<p><strong>股本回报率（ROE）：</strong> Viridian Therapeutics 的 ROE 低于行业平均水平，表明在有效利用股本方面可能面临挑战。ROE 为 <strong>-18.08%</strong>，公司在实现最佳财务回报方面可能面临困难。</p>
<p><strong>资产回报率（ROA）：</strong> 该公司的 ROA 低于行业基准，表明在有效利用资产方面可能面临困难。ROA 为 <strong>-11.3%</strong>，公司可能需要解决从资产中产生满意回报的挑战。</p>
<p><strong>债务管理：</strong> Viridian Therapeutics 的债务与股本比率低于行业平均水平，为 <strong>0.04</strong>，反映出对债务融资的依赖较低，财务策略更为保守。</p>
<h2>分析师评级：它们是什么？</h2>
<p>评级来自分析师，或在银行和金融系统内的专家，他们为特定股票或定义的行业报告（通常每季度一次）。分析师通常从公司电话会议和会议、财务报表以及与重要内部人士的对话中获取信息，以达成他们的决策。</p>
<p>一些分析师还会提供关于增长预期、收益和收入等指标的预测，以进一步指导股票投资。使用分析师评级的投资者应注意，这些专业建议来自于人类，可能会存在错误。</p>
<p><strong>分析师现在推荐哪些股票？</strong></p>
<p>Benzinga Edge 让您即时获取所有主要分析师的评级上调、下调和价格目标。按准确性、上涨潜力等进行排序。<strong>点击这里以领先市场</strong>。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</p>

VRDN

<p>十位分析师对 Viridian Therapeutics (VRDN) 发表了不同的看法，评级从看涨到看跌不等。最近的评估显示情绪出现积极转变，12 个月的平均目标价为 20.00 美元，比之前的目标上涨了 3.78%。分析师们提高或维持了评级，反映了他们对市场动态的反应。在财务方面，Viridian 的收入增长率为 19.44%，但面临净利润率为-89173.26% 和股本回报率为-18.08% 的挑战。该公司保持了 0.04 的保守债务与股本比率，表明对债务融资的依赖较低</p>

<p>10 analysts have expressed a variety of opinions on Viridian Therapeutics VRDN over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<div class="lb-trans"><p>在过去一个季度中，10 位分析师对 Viridian Therapeutics VRDN 表达了各种意见，提供了从看涨到看跌的多样化观点。</p>
</div><p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表总结了他们最近的评级，揭示了过去 30 天内情绪的变化，并与前几个月进行了比较。</p>
</div><table>
<thead>
<tr>
<th></th>
<th><strong>Bullish</strong></th>
<th><strong>Somewhat Bullish</strong></th>
<th><strong>Indifferent</strong></th>
<th><strong>Somewhat Bearish</strong></th>
<th><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td>7</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th><strong>看涨</strong></th>
<th><strong>稍微看涨</strong></th>
<th><strong>无所谓</strong></th>
<th><strong>稍微看跌</strong></th>
<th><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td>7</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
</div><p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $41.2, a high estimate of $61.00, and a low estimate of $34.00. Witnessing a positive shift, the current average has risen by 3.78% from the previous average price target of $39.70.</p>
<div class="lb-trans"><p>分析师评估的 12 个月价格目标揭示了进一步的见解，平均目标为 41.2 美元，最高估计为 61.00 美元，最低估计为 34.00 美元。当前平均价格目标较之前的 39.70 美元上升了 3.78%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2024/1734458424_0.png" alt="" original-src="https://www.benzinga.com/files/images/story/2024/1734458424_0.png"/></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<div class="lb-trans"><h2>分析师评级调查：详尽研究</h2>
</div><p>The perception of Viridian Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通过最近的分析师行动分析金融专家对 Viridian Therapeutics 的看法。以下总结展示了关键分析师、他们的最新评估以及对评级和价格目标的调整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$47.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$44.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Julian Harrison</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$61.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$44.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>上调</td>
<td>超越市场</td>
<td>$47.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright \u0026 Co.</td>
<td>维持</td>
<td>买入</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright \u0026 Co.</td>
<td>维持</td>
<td>买入</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>维持</td>
<td>超越市场</td>
<td>$44.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>维持</td>
<td>买入</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright \u0026 Co.</td>
<td>上调</td>
<td>买入</td>
<td>$34.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>维持</td>
<td>买入</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>维持</td>
<td>买入</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Julian Harrison</td>
<td>BTIG</td>
<td>上调</td>
<td>买入</td>
<td>$61.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>维持</td>
<td>超越市场</td>
<td>$44.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键见解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Viridian Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Viridian Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Viridian Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>采取的行动：</strong> 针对动态市场条件和公司表现，分析师更新他们的建议。无论是 “维持”、“上调” 还是 “下调”，都表明他们对 Viridian Therapeutics 近期发展的反应。这一见解提供了分析师对公司当前状态的快照。</li>
<li><strong>评级：</strong> 分析趋势，分析师提供定性评估，从 “超越市场” 到 “表现不佳”。这些评级传达了对 Viridian Therapeutics 相对于更广泛市场的表现预期。</li>
<li><strong>价格目标：</strong> 分析师提供对 Viridian Therapeutics 股票未来价值的估计。这一比较揭示了分析师预期随时间变化的趋势。</li>
</ul>
</div><p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Viridian Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<div class="lb-trans"><p>将这些分析师评估与其他财务指标结合考虑，可以提供对 Viridian Therapeutics 市场地位的全面理解。保持信息灵通，做出明智的决策，参考我们的评级表。</p>
</div><p><strong>Stay up to date on Viridian Therapeutics analyst ratings.</strong></p>
<div class="lb-trans"><p><strong>保持关注 Viridian Therapeutics 的分析师评级。</strong></p>
</div><p>If you are interested in following small-cap stock news and performance you can start by tracking it here.</p>
<div class="lb-trans"><p>如果您对跟踪小型股新闻和表现感兴趣，可以从这里开始。</p>
</div><h2>Discovering Viridian Therapeutics: A Closer Look</h2>
<div class="lb-trans"><h2>深入了解 Viridian Therapeutics：更近一步</h2>
</div><p>Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.</p>
<div class="lb-trans"><p>Viridian Therapeutics Inc 是一家临床阶段的生物制药公司，致力于开发多种产品候选药物，以治疗患有甲状腺眼病的患者。其产品候选药物 VRDN-001 是一种胰岛素样生长因子-1 受体（IGF-1R）单克隆抗体（mAb），正在开发中以潜在治疗甲状腺眼病患者。</p>
</div><h3>Breaking Down Viridian Therapeutics's Financial Performance</h3>
<div class="lb-trans"><h3>分析 Viridian Therapeutics 的财务表现</h3>
</div><p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 该公司的市值高于行业平均水平，反映出其规模庞大和市场认可度强。</p>
</div><p><strong>Revenue Growth:</strong> Viridian Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>19.44%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增长：</strong> Viridian Therapeutics 在过去 3 个月的收入增长显著。截至 2024 年 9 月 30 日，该公司的收入增长率约为 <strong>19.44%</strong>。这表明公司顶线收益的显著增加。与竞争对手相比，该公司的增长率低于医疗保健行业的平均水平，面临一定困难。</p>
</div><p><strong>Net Margin:</strong> Viridian Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-89173.26%,</strong> the company may face hurdles in effective cost management.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> Viridian Therapeutics 的净利润率低于行业平均水平，表明在维持强劲盈利能力方面可能面临挑战。净利润率为 <strong>-89173.26%</strong>，公司在有效成本管理方面可能面临困难。</p>
</div><p><strong>Return on Equity (ROE):</strong> Viridian Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-18.08%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> Viridian Therapeutics 的 ROE 低于行业平均水平，表明在有效利用股本方面可能面临挑战。ROE 为 <strong>-18.08%</strong>，公司在实现最佳财务回报方面可能面临困难。</p>
</div><p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-11.3%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> 该公司的 ROA 低于行业基准，表明在有效利用资产方面可能面临困难。ROA 为 <strong>-11.3%</strong>，公司可能需要解决从资产中产生满意回报的挑战。</p>
</div><p><strong>Debt Management:</strong> Viridian Therapeutics's debt-to-equity ratio is below the industry average at <strong>0.04</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> Viridian Therapeutics 的债务与股本比率低于行业平均水平，为 <strong>0.04</strong>，反映出对债务融资的依赖较低，财务策略更为保守。</p>
</div><h2>Analyst Ratings: What Are They?</h2>
<div class="lb-trans"><h2>分析师评级：它们是什么？</h2>
</div><p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<div class="lb-trans"><p>评级来自分析师，或在银行和金融系统内的专家，他们为特定股票或定义的行业报告（通常每季度一次）。分析师通常从公司电话会议和会议、财务报表以及与重要内部人士的对话中获取信息，以达成他们的决策。</p>
</div><p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<div class="lb-trans"><p>一些分析师还会提供关于增长预期、收益和收入等指标的预测，以进一步指导股票投资。使用分析师评级的投资者应注意，这些专业建议来自于人类，可能会存在错误。</p>
</div><p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<div class="lb-trans"><p><strong>分析师现在推荐哪些股票？</strong></p>
</div><p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <strong>Click here to stay ahead of the market</strong>.</p>
<div class="lb-trans"><p>Benzinga Edge 让您即时获取所有主要分析师的评级上调、下调和价格目标。按准确性、上涨潜力等进行排序。<strong>点击这里以领先市场</strong>。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</p>
</div>

解析 Viridian Therapeutics：10 位分析师分享他们的看法